NPHLA Tracker · GLP-1 & obesity drug pipeline (ClinicalTrials.gov)
GLP-1 & Obesity Drug Pipeline
Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 181
- Changed in 7 days
- 4
- Latest record
- Jurisdiction
- International / multiple
Records
181 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| The Effects of Glucagon on Hepatic MetabolismNCT05500586Conditions: Obesity; Type2diabetes; NAFLD. Interventions: Glucagon response study | Completed | Phase 1 / Phase 2 | Adrian Vella | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05500586 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475Conditions: Type 2 Diabetes. Interventions: LY3457263; Placebo | Recruiting | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06897475 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099Conditions: Crohn's Disease; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937099 (opens in a new tab)Primary source | System checked NPHLA updated |
| COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086Conditions: Ulcerative Colitis; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06937086 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)NCT07817875Conditions: Obesity. Interventions: Tirzepatide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817875 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06672939 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884Conditions: Urinary Incontinence,Stress. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07202884 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593Conditions: Peripheral Arterial Disease. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07223593 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07241390 (opens in a new tab)Primary source | System checked NPHLA updated |
| ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06672549 (opens in a new tab)Primary source | System checked NPHLA updated |
| ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190Conditions: Overweight; Obesity. Interventions: Eloralintide; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07392190 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide for Treatment of CCCANCT07734870Conditions: Central Centrifugal Cicatricial Alopecia (CCCA). Interventions: Tirzepatide | Recruiting | Phase 2 | Johns Hopkins University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07734870 (opens in a new tab)Primary source | System checked NPHLA updated |
| UNISHAPE-OSA-1: UBT251 Injection Phase Ⅲ Study (OSA-NPAP)NCT07767942Conditions: Obstructive Sleep Apnea, Obesity. Interventions: UBT251; UBT251; Placebo | Not yet recruiting | Phase 3 | The United Bio-Technology (Hengqin) Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07767942 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 DiabetesNCT07890376Conditions: Obesity; Overweight. Interventions: LY4086940; Placebo | Not yet recruiting | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07890376 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMPLIFY-1: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNCT07881432Conditions: Obesity. Interventions: eloralintide and tirzepatide; Eloralintide; Tirzepatide; Placebo | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07881432 (opens in a new tab)Primary source | System checked NPHLA updated |
| WISPER: Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerNCT07909889Conditions: Breast Cancer (Early Breast Cancer); Obesity. Interventions: Semaglutide (Wegovy®) | Not yet recruiting | Phase 2 | Aarhus University Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07909889 (opens in a new tab)Primary source | System checked NPHLA updated |
| STEP HFpEF DM: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNCT04916470Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2. Interventions: Semaglutide; Placebo (Semaglutide) | Completed | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04916470 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesNCT06924320Conditions: Obesity and Obesity-related Medical Conditions. Interventions: MET233 and MET097; Placebo; MET097 | Completed | Phase 1 / Phase 2 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06924320 (opens in a new tab)Primary source | System checked NPHLA updated |
| Tirzepatide and Organ-specific Biological AgingNCT07906041Conditions: Longevity; Preventive Medicine; Biological Ageing. Interventions: Tirzepatide | Enrolling by invitation | Phase 2 | Atria Research and Global Health Institute (ARGHI) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07906041 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseNCT07907965Conditions: Diabetic Kidney Disease (DKD); Type 2 Diabetes; Albuminuria. Interventions: Guominkang Granules; Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen | Active, not recruiting | Phase 2 | Beijing University of Chinese Medicine | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07907965 (opens in a new tab)Primary source | System checked NPHLA updated |
| TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep ApnoeaNCT07846865Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Interventions: Continuous Positive Airway Pressure; Tirzepatide | Not yet recruiting | Phase 2 / Phase 3 | Woolcock Institute of Medical Research | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07846865 (opens in a new tab)Primary source | System checked NPHLA updated |
| A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538Conditions: Obesity. Interventions: ARO-INHBE; Placebo; Tirzepatide | Active, not recruiting | Phase 1 / Phase 2 | Arrowhead Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06700538 (opens in a new tab)Primary source | System checked NPHLA updated |
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050Conditions: Obesity. Interventions: Survodutide; Placebo | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850050 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRI-MR: An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderNCT07693608Conditions: Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders. Interventions: Tirzepatide | Active, not recruiting | Phase 2 | University of Texas Southwestern Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07693608 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in NondiabeticsNCT04466566Conditions: Healthy. Interventions: Saline; Exendin-9,39; Liraglutide | Completed | Phase 3 | Adrian Vella | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04466566 (opens in a new tab)Primary source | System checked NPHLA updated |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Interventions: Survodutide; Placebo | Recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06632444 (opens in a new tab)Primary source | System checked NPHLA updated |
| Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)NCT03884075Conditions: Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease. Interventions: Semaglutide | Recruiting | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03884075 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Semaglutide in HIV-Associated LipohypertrophyNCT04019197Conditions: HIV/AIDS; Lipohypertrophy; Obesity. Interventions: Semaglutide Injectable Product; Placebo | Completed | Phase 2 | Case Western Reserve University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04019197 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESOLVE-2: Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)NCT07220629Conditions: Obesity. Interventions: NT-0796; Placebo | Completed | Phase 2 | Rezera (formerly NodThera Limited) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07220629 (opens in a new tab)Primary source | System checked NPHLA updated |
| H24LEAP2: Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and ObesityNCT07897383Conditions: Obesity & Overweight. Interventions: Liver-expressed antimicrobial peptide 2; Placebo | Not yet recruiting | Phase 1 / Phase 2 | University Hospital, Gentofte, Copenhagen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07897383 (opens in a new tab)Primary source | System checked NPHLA updated |
| SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT07855900Conditions: Obesity. Interventions: Survodutide | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07855900 (opens in a new tab)Primary source | System checked NPHLA updated |
| Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979Conditions: Obesity; Overweight. Interventions: ABBV-295; Placebo | Recruiting | Phase 2 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07752979 (opens in a new tab)Primary source | System checked NPHLA updated |
| T-STEM: Randomized Controlled Trial of Tirzepatide for Methamphetamine Use DisorderNCT07825857Conditions: Methamphetamine Use Disorder. Interventions: Tirzepatide; Placebo (saline) | Recruiting | Phase 2 | University of Texas Southwestern Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07825857 (opens in a new tab)Primary source | System checked NPHLA updated |
| NATRIURETIC: Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" TrialNCT04535960Conditions: Type 2 Diabetes Mellitus. Interventions: Empagliflozin 25 MG + Liraglutide 1.8 MG; Liraglutide 1.8 MG + Empagliflozin 25 MG | Completed | Phase 2 | University Health Network, Toronto | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04535960 (opens in a new tab)Primary source | System checked NPHLA updated |
| BARI-STEP: Semaglutide 2.4 mg in Patients With Poor Weight-lossNCT05073835Conditions: Obesity; Diabetes; Metabolic Syndrome. Interventions: Semaglutide 3 mg; Placebo | Completed | Phase 3 | University College, London | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05073835 (opens in a new tab)Primary source | System checked NPHLA updated |
| RISE-1: Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without DiabetesNCT07896265Conditions: Overweight or Obesity Without Diabetes. Interventions: Olatorepatide; Placebo | Not yet recruiting | Phase 3 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07896265 (opens in a new tab)Primary source | System checked NPHLA updated |
| INLIGHT: A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or ObesityNCT06842186Conditions: Overweight and Obesity. Interventions: WVE-007 | Recruiting | Phase 1 / Phase 2 | Wave Life Sciences USA, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06842186 (opens in a new tab)Primary source | System checked NPHLA updated |
| SEMA-T1D-BODY: Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.NCT07891156Conditions: Type 1 Diabetes; Overweight , Obesity. Interventions: Semaglutide; Placebo | Recruiting | Phase 2 / Phase 3 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07891156 (opens in a new tab)Primary source | System checked NPHLA updated |
| Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin ResistanceNCT04578652Conditions: Obesity, Childhood; Insulin Resistance. Interventions: Metformin 850 mg oral tablet bid; Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resi… | Recruiting | Phase 3 | University of Alberta | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04578652 (opens in a new tab)Primary source | System checked NPHLA updated |
| CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightNCT06151964Conditions: Overweight and Obesity. Interventions: AZD9550; placebo; AZD9550 and AZD6234 | Active, not recruiting | Phase 1 / Phase 2 | AstraZeneca | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06151964 (opens in a new tab)Primary source | System checked NPHLA updated |
| INFLAM MOTION: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829Conditions: Knee Osteoarthritis; Synovitis of Knee. Interventions: 4P004; Placebo (NaCl 0.9%) | Completed | Phase 2 | 4Moving Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07225829 (opens in a new tab)Primary source | System checked NPHLA updated |
| Eluminate-2: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213Conditions: Type 2 Diabetes Mellitus. Interventions: Elecoglipron; Semaglutide | Recruiting | Phase 3 | AstraZeneca | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07662213 (opens in a new tab)Primary source | System checked NPHLA updated |
| ENI-SPIRE-2: A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsNCT07889648Conditions: Type 2 Diabetes Mellitus. Interventions: Enicepatide; Tirzepatide | Not yet recruiting | Phase 3 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07889648 (opens in a new tab)Primary source | System checked NPHLA updated |
| GUT BOOST: Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With ObesityNCT07823452Conditions: Obesity & Overweight. Interventions: gut-brain axis (GLP-1)-activating food carbohydrate; starch-based placebo control (commercial maltodextrin) | Not yet recruiting | Phase 2 | Indiana University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07823452 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaNCT07107334Conditions: Endometrioid Endometrial Adenocarcinoma. Interventions: Glucagon-like peptide 1 receptor agonist | Recruiting | Phase 2 | University of Florida | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07107334 (opens in a new tab)Primary source | System checked NPHLA updated |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyNCT07502508Conditions: Type 2 Diabetes. Interventions: icovamenib 100 mg; Placebo | Recruiting | Phase 2 | Biomea Fusion Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07502508 (opens in a new tab)Primary source | System checked NPHLA updated |
| Reducing Innate Inflammation in New Onset Type 1 DiabetesNCT04335656Conditions: Type 1 Diabetes; type1diabetes; Type 1 Diabetes Mellitus. Interventions: Lactiplantibacillus plantarum; Placebo | Active, not recruiting | Phase 2 | Medical College of Wisconsin | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04335656 (opens in a new tab)Primary source | System checked NPHLA updated |
| IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With ObesityNCT07884058Conditions: Obesity & Overweight. Interventions: IGOB131; Dextrin | Not yet recruiting | Phase 2 | University of Yaounde 1 | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07884058 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374Conditions: Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus. Interventions: aleniglipron; aleniglipron; aleniglipron; Placebo | Recruiting | Phase 3 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07654374 (opens in a new tab)Primary source | System checked NPHLA updated |
| PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility StudyNCT07874828Conditions: Sarcoma,Soft Tissue. Interventions: Tirzepatide | Recruiting | Phase 2 | M.D. Anderson Cancer Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07874828 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.
When a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.
What does it cover?
Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.
What are its limitations?
Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.